Yamaguchi Y, Takenaga M, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R
School of Medicine, Institute of Medical Science, St. Marianna University, Sugao 2-16-1 Miyamae-ku, Kawasaki-shi, Kanagawa-ken, Japan.
J Control Release. 2002 Jun 17;81(3):235-49. doi: 10.1016/s0168-3659(02)00060-3.
We investigated the controlled release of human insulin at an initial stage from poly(DL-lactic-co-glycolic acid) (PLGA, M(w) 6600) spherical matrices. PLGA microcapsules were prepared by the novel solvent evaporation multiple emulsion process. When the crystalline insulin was dispersed in dichloromethane as solid-in-oil (S/O) dispersion, it was found that most of insulin molecules were inlaid on the surface of PLGA microcapsules. Consequently, insulin-loaded PLGA microcapsules exhibited marked rapid release of insulin within several hours in both in vivo and in vitro experiments. On the other hand, the addition of glycerol or water in the primary dichloromethane dispersion results in drastically suppressed initial release. It was found by SEM observation that water- or glycerol-in-oil (W/O or G/O) type mini-emulsion droplets with a mean diameter of 300-500 nm were formed in this primary solution. This phenomenon can be theoretically presumed to occur because insulin and PLGA molecules, having amphiphilic properties, converge on the interface between the hydrophilic additive and dichloromethane. Hence, insulin molecules heterogeneously located in the inside of PLGA microcapsules, not on the surface, would be gradually released with PLGA hydrolytic decomposition. As an additional effect of glycerol, the initial burst was further suppressed due to the decrease of the glass transition temperature of PLGA from 42.5 to 36.7 degrees C. Since the annealing of PLGA molecules took place at around 37 degrees C, the porous structure of microspheres immediately disappeared after immersion in PBS or subcutaneous administration. The insulin diffusion through the water-filled pores would be effectively prevented. The strict controlled initial release of insulin from the PLGA microsphere suggested the possibility of utilization in insulin therapy for type I diabetic patients who need construction of a basal insulin profile.
我们研究了聚(DL-乳酸-共-乙醇酸)(PLGA,分子量6600)球形基质在初始阶段对人胰岛素的控释情况。PLGA微胶囊通过新型溶剂蒸发复乳法制备。当结晶胰岛素作为油包固(S/O)分散体分散在二氯甲烷中时,发现大多数胰岛素分子镶嵌在PLGA微胶囊的表面。因此,载胰岛素的PLGA微胶囊在体内和体外实验中均在数小时内表现出明显的胰岛素快速释放。另一方面,在初始二氯甲烷分散体中加入甘油或水会导致初始释放大幅受到抑制。通过扫描电子显微镜观察发现,在该初始溶液中形成了平均直径为300 - 500 nm的水包油(W/O)或甘油包油(G/O)型微乳液滴。从理论上推测,这种现象的发生是因为具有两亲性的胰岛素和PLGA分子会聚集在亲水性添加剂与二氯甲烷之间的界面上。因此,位于PLGA微胶囊内部而非表面的胰岛素分子会随着PLGA的水解分解而逐渐释放。作为甘油的额外作用,由于PLGA的玻璃化转变温度从42.5℃降至36.7℃,初始突释进一步受到抑制。由于PLGA分子在约37℃时发生退火,微球的多孔结构在浸入磷酸盐缓冲盐水(PBS)或皮下给药后立即消失。胰岛素通过充满水的孔隙的扩散将被有效阻止。PLGA微球对胰岛素严格的初始释放控制表明,其有可能用于需要构建基础胰岛素谱的I型糖尿病患者的胰岛素治疗。